Read + Share
Becerra-Chauca N, Nieto-Gutierrez W, Taype-Rondan A. 6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer?
Decision-making in a resource-limited setting. Lancet Oncol 2022;23:e100.
PMID: 35240085
|
 |
|
Becerra-Chauca N, Nieto-Gutierrez W, Taype-Rondan A. 6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer?
Decision-making in a resource-limited setting. Lancet Oncol 2022;23:e100.
PMID: 35240085
|
|
|
|